In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amarantus BioScience Holdings Inc.

www.amarantus.com

Latest From Amarantus BioScience Holdings Inc.

Pacts In Medtech: Amarantus And Todos Form Breakthrough Diagnostics Inc.; Edwards Teams Up With Bay Labs To Find Heart Disease

Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, R&D partnerships and commercial collaborations. This edition covers industry pacts that were sealed in November and December 2018.

Pacts in Medtech Deals

Tech Transfer Roundup: Amgen Teams With MD Anderson To Accelerate Early-Stage Cancer Candidates

In a busy month, MD Anderson also partners with Ipsen on an unspecified cancer drug and licenses poziotinib IP to Spectrum. Using IP from UCLA, Bloom launches with focus on neuroprotective epilepsy therapies.

Deals Intellectual Property

Horama's Gene Therapies For Retinal Diseases: Fast Followers?

French biotech Horama has built-up its executive team and has two potential gene therapies for retinitis pigmentosa nearing the clinic.

Clinical Trials Ophthalmic

OptiKira Pursuing A Novel Small-Molecule Approach To Retinitis Pigmentosa

An early-stage, small-molecule approach to the treatment of retinitis pigmentosa being developed by US biotech OptiKira may have potential benefits over more advanced gene and cell therapies for the blindness-causing condition.

Market Intelligence Ophthalmic
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Neurology, Nervous System
  • Ophthalmic
  • Otolaryngology
  • Alias(es)
  • Amarantus BioSciences Inc.
  • Amarantus BioScience Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Amarantus BioScience Holdings Inc.
  • Senior Management
  • Gerald E Commissiong, Pres. & CEO
    Barney Monte, Interim COO & CFO
    John W Commissiong, PhD, CSO
    Elise Brownell, PhD, SVP, Operations & Project Mgmt.
  • Contact Info
  • Amarantus BioScience Holdings Inc.
    Phone: (917) 686-5317
    110 Wall St.
    New York, NY 10005
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register